We read with interest the study by Rosenhek et al 1 demonstrating a lower rate of aortic valve disease progression as indicated by Doppler echocardiographic jet velocity or valve area in patients treated with a statin but not with an angiotensinconverting enzyme (ACE) inhibitor. The authors also found that of 211 patients, 102 were receiving established treatment with ACE inhibitors. As was observed in the accompanying editorial, 2 this study adds to existing published evidence that the risk of giving ACE inhibitors to patients with aortic stenosis is largely theoretical. 3, 4 The idea that these drugs will cause severe hypotension as a result of vasodilatation in the face of fixed left ventricular (LV) outflow obstruction appears to be either incorrect or at least describes a rare event. There are no published reports of severe hypotension or other adverse effects. 3 Although ACE inhibitors do not appear to reduce the progression of valvular stenosis, they may have a favorable impact on the LV hypertrophic and remodeling response to pressure overload. Arguably, this is of greater importance than any effects on the diseased aortic valve. The valve will ultimately be replaced, but the left ventricle will not, and its structure and function are important determinants of prognosis. LV hypertrophy is a major risk factor for adverse cardiac events and has been specifically identified as an important predictor of outcome after aortic valve replacement. 5,6 Angiotensin II has a central role in the development of LV hypertrophy, myocardial contractile failure, and diastolic dysfunction in response to pressure overload, and animal evidence shows that this adverse LV remodeling is attenuated by ACE inhibition. 4 Despite the lack of effect on valvular stenosis, Rosenhek and colleagues' study is important in highlighting the safety of this therapy so that prospective studies of the effects of ACE inhibitors or angiotensin II receptor blockers in aortic stenosis may be designed. The initial aim would be to evaluate their long-term effects on LV structure and function. If beneficial effects are observed, then clinical outcome studies should be undertaken. but not angiotensinconverting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004;110:1291-1295. 2. Rajamannan NM, Otto CM. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation. 2004;110:1180 -1182. 3. Cox NL, Abdul-Hamid AR, Mulley GP. Why deny ACE inhibitors to patients with aortic stenosis? Lancet. 1998;352:111-112. 4. Routledge HC, Townend JN. ACE inhibition in aortic stenosis: dangerous medicine or golden opportunity? J Hum Hypertens. 2001;15:659 -667. 5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566. 6. Lund O. Preoperative risk evaluation and stratification of long-term survival after valve replacement for aortic stenosis: reasons for earlier operative intervention. Circulation. 1990;82:124 -139.
Letter Regarding Article by Rosenhek et al, "Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis"
To the Editor:
We read with interest the study by Rosenhek et al 1 demonstrating a lower rate of aortic valve disease progression as indicated by Doppler echocardiographic jet velocity or valve area in patients treated with a statin but not with an angiotensinconverting enzyme (ACE) inhibitor. The authors also found that of 211 patients, 102 were receiving established treatment with ACE inhibitors. As was observed in the accompanying editorial, 2 this study adds to existing published evidence that the risk of giving ACE inhibitors to patients with aortic stenosis is largely theoretical. 3, 4 The idea that these drugs will cause severe hypotension as a result of vasodilatation in the face of fixed left ventricular (LV) outflow obstruction appears to be either incorrect or at least describes a rare event. There are no published reports of severe hypotension or other adverse effects. 3 Although ACE inhibitors do not appear to reduce the progression of valvular stenosis, they may have a favorable impact on the LV hypertrophic and remodeling response to pressure overload. Arguably, this is of greater importance than any effects on the diseased aortic valve. The valve will ultimately be replaced, but the left ventricle will not, and its structure and function are important determinants of prognosis. LV hypertrophy is a major risk factor for adverse cardiac events and has been specifically identified as an important predictor of outcome after aortic valve replacement. 5, 6 Angiotensin II has a central role in the development of LV hypertrophy, myocardial contractile failure, and diastolic dysfunction in response to pressure overload, and animal evidence shows that this adverse LV remodeling is attenuated by ACE inhibition. 4 Despite the lack of effect on valvular stenosis, Rosenhek and colleagues' study is important in highlighting the safety of this therapy so that prospective studies of the effects of ACE inhibitors or angiotensin II receptor blockers in aortic stenosis may be designed. The initial aim would be to evaluate their long-term effects on LV structure and function. If beneficial effects are observed, then clinical outcome studies should be undertaken. 
Response
We agree with Drs Routledge and Townend that the findings of our study 1 indicate that a significant number of patients with aortic stenosis seen in our daily clinical practice receive treatment with angiotensin-converting enzyme (ACE) inhibitors because of concomitant arterial hypertension (102 of 211 patients), and that, from the overall impression, use of ACE inhibitors seems to be associated with little risk. The observation that a high proportion of patients with documented aortic stenosis already receives ACE inhibitors is shared by others. 2 Because of its retrospective nature (rates of hemodynamic progression were assessed in patients having Ն2 echocardiograms), however, our study 1 was not designed to assess the safety of ACE inhibitors' use in patients with aortic stenosis. In particular, it must be pointed out that no clinical end points were recorded. Furthermore, the patients were already taking the inhibitor, and the study provides no information with regard to initiation of ACE inhibitor therapy. On the other hand, it is worth mentioning that patients receiving ACE inhibitors covered the whole range of aortic stenosis severity, with an average peak aortic jet velocity of 4.0 m/s (range 2.5 to 6.4 m/s).
Two other recent studies suggest that the use of ACE inhibitors may be safe in aortic stenosis: O'Brien and colleagues have recently demonstrated that the use of ACE inhibitors is safe and well tolerated in patients with mild to moderate aortic stenosis with preserved left ventricular function. 2 Chockalingam and colleagues studied the use of ACE inhibitors in symptomatic patients with severe aortic stenosis who were not candidates for surgery. ACE inhibitors seemed to be well tolerated, but patients with reduced left ventricular function were prone to develop hypotension. 3 Several studies have demonstrated that left ventricular hypertrophy is of prognostic importance in patients with arterial hypertension 4, 5 ; however, these conclusions cannot be simply extrapolated to patients with aortic stenosis in whom the prognostic implications of left ventricular hypertrophy remain insufficiently studied.
We believe that further data in support of the authors' hypothesis that ACE inhibitors can improve the outcome of aortic stenosis by favorably influencing left ventricular remodeling are required before the initiation of such prospective studies. The findings of our study do not suggest the initiation of such studies, as they do not support prospective randomized studies of the effects of ACE inhibitors on hemodynamic progression of aortic stenosis.
